Cargando…

Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis

Abnormal overexpression of CXCL13 is observed in many inflamed tissues and in particular in autoimmune diseases. Myasthenia gravis (MG) is a neuromuscular disease mainly mediated by anti-acetylcholine receptor autoantibodies. Thymic hyperplasia characterized by ectopic germinal centers (GCs) is a co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiss, Julia Miriam, Robinet, Marieke, Aricha, Revital, Cufi, Perrine, Villeret, Bérengère, Lantner, Frida, Shachar, Idit, Fuchs, Sara, Souroujon, Miriam C., Berrih-Aknin, Sonia, Le Panse, Rozen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper: Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884937/ https://www.ncbi.nlm.nih.gov/pubmed/26771137 http://dx.doi.org/10.18632/oncotarget.6885

Ejemplares similares

Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models
por: Robinet, Marieke, et al.
Publicado: (2017)

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Autoimmune Thyroiditis and Myasthenia Gravis
por: Lopomo, Angela, et al.
Publicado: (2017)

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
por: Maurer, Marie, et al.
Publicado: (2015)

Regulatory B cells in myasthenia gravis are differentially affected by therapies
por: Yilmaz, Vuslat, et al.
Publicado: (2018)

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker
por: Punga, Tanel, et al.
Publicado: (2014)

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
por: Cron, Mélanie A., et al.
Publicado: (2019)

Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
por: Cron, Mélanie A., et al.
Publicado: (2020)

Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects
por: Truffault, Frédérique, et al.
Publicado: (2020)

Altered expression of fragile X mental retardation-1 (FMR1) in the thymus in autoimmune myasthenia gravis
por: Thomas, Scott, et al.
Publicado: (2021)

Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis
por: Villegas, José A., et al.
Publicado: (2023)

Single-cell mass cytometry on peripheral cells in Myasthenia Gravis identifies dysregulation of innate immune cells
por: Verdier, Julien, et al.
Publicado: (2023)

CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients
por: Wang, Cuini, et al.
Publicado: (2016)

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis
por: Behin, Anthony, et al.
Publicado: (2018)

MuSK EAMG: Immunological Characterization and Suppression by Induction of Oral Tolerance
por: Reuveni, Debby, et al.
Publicado: (2020)

Mad3 Negatively Regulates B Cell Differentiation in the Spleen by Inducing Id2 Expression
por: Gore, Yael, et al.
Publicado: (2010)

Role of miRNAs in Normal and Myasthenia Gravis Thymus
por: Cron, Mélanie A., et al.
Publicado: (2020)

CXCL13 antibody for the treatment of autoimmune disorders
por: Klimatcheva, Ekaterina, et al.
Publicado: (2015)

Comment on “Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis”
por: Le Panse, Rozen
Publicado: (2017)

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis
por: Cavalcante, Paola, et al.
Publicado: (2011)

Suppression of lymphocyte apoptosis in spleen by CXCL13 after porcine circovirus type 2 infection and regulatory mechanism of CXCL13 expression in pigs
por: Liu, Gen, et al.
Publicado: (2019)

CXCL13 in laboratory diagnosis of Lyme neuroborreliosis—the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples
por: Haglund, Sofie, et al.
Publicado: (2021)

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients
por: Panse, J, et al.
Publicado: (2008)

CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance
por: Masouris, Ilias, et al.
Publicado: (2021)

Role of serum CXCL9 and CXCL13 in predicting infection after kidney transplant: A STROBE study
por: Yan, Lin, et al.
Publicado: (2021)

Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on “Chemokine CXCL13 in serum, CSF, and blood–CSF barrier function”
por: DiSano, Krista D., et al.
Publicado: (2021)

The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis
por: Dersch, R, et al.
Publicado: (2015)

LPA Promotes T Cell Recruitment through Synthesis of CXCL13
por: Hui, Weili, et al.
Publicado: (2015)

The chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis
por: Henningsson, Anna J., et al.
Publicado: (2018)

Regulated Production of CXCL13 within the Central Nervous System
por: Irani, David N.
Publicado: (2016)

Duality of B Cell-CXCL13 Axis in Tumor Immunology
por: Rubio, Angel J., et al.
Publicado: (2020)

CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer
por: Zhang, Guolin, et al.
Publicado: (2020)

CXCL13 concentration in latent syphilis patients with treatment failure
por: Zhang, Yan, et al.
Publicado: (2020)

Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases
por: Pan, Zijian, et al.
Publicado: (2022)

Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome
por: Chatzis, Loukas, et al.
Publicado: (2021)

Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease
por: Han, Jae Ho, et al.
Publicado: (2015)

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis
por: Avidan, Nili, et al.
Publicado: (2014)

The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial
por: Birnbaum, Simone, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bremde0l3to6032f154861ntv2